Last reviewed · How we verify
ABBV-1354
At a glance
| Generic name | ABBV-1354 |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder (PHASE2)
- A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants (PHASE1)
- A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants (PHASE1)
- A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-1354 CI brief — competitive landscape report
- ABBV-1354 updates RSS · CI watch RSS
- AbbVie portfolio CI